PLAAT4 and Miyoshi myopathy: Altogether, our data also proposes that RARRES3 may be a useful biomarker for the clinical application of VS-5584 treatment, and analyses of patient databases UAMS and APEX suggest that VS-5584 may be less efficient for MM patients with 11q13 translocations but more successful in patients with maf translocations.